|
Author
|
Regimen (mg)
|
Acute CR (%)
|
Delayed CR (%)
|
Overall CR (%)
|
Chemotherapy
|
|---|
|
Eisenberg et al. (2003)
|
Palo (0.25)
|
63
|
54
|
46
|
MEC
|
|
Palo (0.75)
|
57.1
|
56.6
|
47.1
|
|
Celio et al. (2011)
|
Palo (0.25) + Dex (8) day 1
|
88.6
|
68.7
|
67.5
|
MEC
|
|
Palo (0.25) + Dex (8) days 1-3
|
84.3
|
77.7
|
71.1
|
|
Tanioka et al. (2013)
|
Gra (1) + Dex (12) + Ap
|
97.8
|
62.2
|
62.2
|
CBDCA-based
|
|
Gra (1) + Dex(12)
|
95.7
|
52.2
|
52.2
|
|
Hesketh et al. (2016)
|
Gra (2) day1-3 + Dex (20) + Rol (180)
|
91.7
|
82.3
|
80.2
|
CBDCA-based
|
|
Gra (2 mg) days1-3 + Dex (20 mg)
|
88.0
|
65.6
|
64.6
|
|
Yahata et al. (2016)
|
Gra (1/4) + Dex (20) + Ap
|
94.0
|
63.6
|
61.6
|
CBDCA + PAC
|
|
Gra (1/4) + Dex (20)
|
90.4
|
49.3
|
47.3
|
|
Present study
|
Palo (0.75) + Dex (9.9) + Ap
|
100
|
91.9
|
91.9
|
CBDCA-based
|
- Doses of Ap were the standard doses recommended by various guidelines such as 125 mg on day 1 and 80 mg on days 2 and 3. “MEC” in the chemotherapy column indicates that the MEC was not specified
-
CR complete response, Palo palonosetron, Gra granisetron, Dex dexamethasone, Ap aprepitant, Rol rolapitant, MEC moderately emetogenic chemotherapy, CBDCA carboplatin, PAC paclitaxel
